IMMUNOTECH-BRTS Stock (02953.HK) Real-time Quotes - Financial Data - Analyst Ratings

Company Encyclopedia

IMMUNOTECH-BRTS

02953.HK

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. The company’s core product is EAL, a multi-target cellular immunotherapy product that is in Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for relapsed and refractory diffuse large B-cell lymphoma; and TCR-T cell series products to treat solid tumors. In addition, the company develops pre-clinical products, such as aT19 to treat hematologic malignancies; YT003 and YT008 for post transplantation infections; YT007 for solid tumors; and VAC-aT19 for hematologic malignancies.

344.95 B

02953.HKMarket value -Rank by Market Cap -/-

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
No Data

News

Hong Kong Stock Movement: IMMUNOTECH-BRTS Shares Surge 20.55%

IMMUNOTECH-BRTS surged 20.55%; ZTE Corporation rose 4.37%, with a transaction volume of HKD 1.37 billion; Yangtze Optical Fibre and Cable fell 1.85%, with a transaction volume of HKD 866 million; BYD Electronics increased by 2.17%, with a transaction volume of HKD 482 million; VTech Holdings rose 2.03%, with a market capitalization of HKD 15.3 billion

HK Stock Movers Tracker·10/20/2025 13:26

02953

0.00%

HK Stock Movers Tracker·10/20/2025 13:26

02953

0.00%

WINSHINE SCI: Chen Yuyi has been appointed as the company secretary

WINSHINE SCI announced that starting from October 17, 2025, Richard Yu will resign as the company secretary and authorized representative, and Chen Yuyi has been appointed as the new company secretary and authorized representative

Zhitong·10/17/2025 17:29

Zhitong·10/17/2025 17:29

WINSHINE SCI plans a "1 for 7" rights issue, netting approximately HKD 176.5 million

WINSHINE SCI announced plans for a rights issue, with a basis of 7 new shares for every 1 existing share held, at a subscription price of HKD 0.14 per share, expected to raise up to approximately HKD 182 million. This subscription price represents a discount of about 23.5% to the closing price on October 14, 2025. If the rights issue is fully subscribed, the net proceeds are expected to be approximately HKD 176.5 million

Zhitong·10/15/2025 12:15

Zhitong·10/15/2025 12:15

WINSHINE SCI plans to offer a 23.5% discount on a "1 for 7" rights issue, netting HKD 177 million

WINSHINE SCI plans to conduct a rights issue based on a "1 for 7" ratio, issuing up to 1.3 billion shares at a subscription price of HKD 0.14 per share, representing a discount of approximately 23.5% to the closing price on the previous day. If the rights issue is fully subscribed, it is expected to raise approximately HKD 177 million, of which 66% will be used to repay loans and 34% for general working capital. The board has received irrevocable commitments from major shareholder Wang Jingyu and his wholly-owned company Peak Access to ensure acceptance of the rights issue share allocation and not to sell shares before the completion of the rights issue

AASTOCKS·10/15/2025 12:09

AASTOCKS·10/15/2025 12:09